Uncategorized - December 18, 2014
Xellia Forms Advisory Board
Xellia Pharmaceuticals, which focuses on providing important anti-infective treatments against serious and often life-threatening infections, announced the formation of a new Scientific Advisory Board (SAB). The SAB brings together leading international scientific and clinical advisors with expertise in infectious diseases, clinical microbiology, respiratory medicines and drug research and development. The SAB Chairman will be Professor […]
Drug Development Pharma - November 24, 2014
Xellia Opens New Facility
Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against
Acquisition - May 24, 2013
Novo A/S acquires Xellia Pharmaceuticals
Novo A/S, the holding company of the Novo Group, has purchased all shares in pharmaceutical group Xellia Pharmaceuticals for approximately USD 700 million. Xellia will now revert to Danish ownership with headquarters in Copenhagen, Denmark following the recent acquisition. Xellia Pharmaceuticals focuses on development, manufacturing and global commercialization of anti-infective therapies. Since its spin-out from Alpharma […]
